JP2019518460A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019518460A5 JP2019518460A5 JP2018565336A JP2018565336A JP2019518460A5 JP 2019518460 A5 JP2019518460 A5 JP 2019518460A5 JP 2018565336 A JP2018565336 A JP 2018565336A JP 2018565336 A JP2018565336 A JP 2018565336A JP 2019518460 A5 JP2019518460 A5 JP 2019518460A5
- Authority
- JP
- Japan
- Prior art keywords
- engineered
- composition
- regulatory
- cell
- cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 210000003289 regulatory T cell Anatomy 0.000 claims description 56
- 102000000887 Transcription factor STAT Human genes 0.000 claims description 36
- 108050007918 Transcription factor STAT Proteins 0.000 claims description 36
- 238000000034 method Methods 0.000 claims description 25
- 230000000694 effects Effects 0.000 claims description 16
- 101000617830 Homo sapiens Sterol O-acyltransferase 1 Proteins 0.000 claims description 10
- 102100021993 Sterol O-acyltransferase 1 Human genes 0.000 claims description 10
- 101000697584 Streptomyces lavendulae Streptothricin acetyltransferase Proteins 0.000 claims description 10
- 210000002865 immune cell Anatomy 0.000 claims description 7
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims description 6
- 102000001712 STAT5 Transcription Factor Human genes 0.000 claims description 6
- 108010029477 STAT5 Transcription Factor Proteins 0.000 claims description 6
- 108091008874 T cell receptors Proteins 0.000 claims description 6
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 claims description 6
- 210000004027 cell Anatomy 0.000 claims description 4
- 208000023275 Autoimmune disease Diseases 0.000 claims description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 2
- 208000035475 disorder Diseases 0.000 claims description 2
- 238000000338 in vitro Methods 0.000 claims description 2
- 208000027866 inflammatory disease Diseases 0.000 claims description 2
- 230000002757 inflammatory effect Effects 0.000 claims description 2
- 230000001105 regulatory effect Effects 0.000 claims description 2
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022021158A JP2022058995A (ja) | 2016-06-16 | 2022-02-15 | 操作されたＴｒｅｇ細胞 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662351104P | 2016-06-16 | 2016-06-16 | |
| US62/351,104 | 2016-06-16 | ||
| PCT/US2017/037794 WO2017218850A1 (en) | 2016-06-16 | 2017-06-15 | Engineered treg cells |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022021158A Division JP2022058995A (ja) | 2016-06-16 | 2022-02-15 | 操作されたＴｒｅｇ細胞 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019518460A JP2019518460A (ja) | 2019-07-04 |
| JP2019518460A5 true JP2019518460A5 (enExample) | 2020-07-27 |
Family
ID=60663377
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018565336A Withdrawn JP2019518460A (ja) | 2016-06-16 | 2017-06-15 | 操作されたＴｒｅｇ細胞 |
| JP2022021158A Pending JP2022058995A (ja) | 2016-06-16 | 2022-02-15 | 操作されたＴｒｅｇ細胞 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022021158A Pending JP2022058995A (ja) | 2016-06-16 | 2022-02-15 | 操作されたＴｒｅｇ細胞 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20190322983A1 (enExample) |
| EP (1) | EP3472305A4 (enExample) |
| JP (2) | JP2019518460A (enExample) |
| CN (1) | CN109415698A (enExample) |
| AU (1) | AU2017285319A1 (enExample) |
| CA (1) | CA3027546A1 (enExample) |
| MA (1) | MA45498A (enExample) |
| WO (1) | WO2017218850A1 (enExample) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL265962B2 (en) * | 2016-10-10 | 2025-10-01 | Nat Institute For Biotechnology In The Negev Ltd | Non-cytotoxic adapted cells and their use |
| GB201714718D0 (en) | 2017-09-13 | 2017-10-25 | Autolus Ltd | Cell |
| WO2019178518A1 (en) * | 2018-03-16 | 2019-09-19 | The Regents Of The University Of California | Cellular signaling domain engineering in chimeric antigen receptor-modified regulatory t cells |
| CA3105953A1 (en) | 2018-07-09 | 2020-01-16 | Flagship Pioneering Innovations V, Inc. | Fusosome compositions and uses thereof |
| GB201814203D0 (en) * | 2018-08-31 | 2018-10-17 | King S College London | Engineered regulatory t cell |
| US20230043255A1 (en) | 2018-11-14 | 2023-02-09 | Flagship Pioneering Innovations V, Inc. | Fusosome compositions for t cell delivery |
| CA3128216A1 (en) * | 2019-02-01 | 2020-08-06 | KSQ Therapeutics, Inc. | Gene-regulating compositions and methods for improved immunotherapy |
| EP3997212A4 (en) | 2019-07-09 | 2024-01-17 | The Children's Mercy Hospital | GENETICALLY MODIFIED REGULATORY T CELLS |
| US20230060230A1 (en) * | 2020-01-27 | 2023-03-02 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Hdac6-inhibited human regulatory t cells |
| EP4110801A1 (en) | 2020-02-25 | 2023-01-04 | Quell Therapeutics Limited | Chimeric receptors for use in engineered cells |
| GB202102637D0 (en) | 2021-02-24 | 2021-04-07 | Quell Therapeutics Ltd | Engineered regulatory t cell |
| AU2024212695A1 (en) | 2023-01-23 | 2025-08-14 | Medizinische Hochschule Hannover | Anti-entpd3 chimeric antigen receptor |
| EP4403580A1 (en) | 2023-01-23 | 2024-07-24 | Medizinische Hochschule Hannover | Anti-entpd3 chimeric antigen receptor |
| KR20250165594A (ko) | 2023-02-07 | 2025-11-26 | 퀠 테라퓨틱스 리미티드 | Treg 세포의 배양 방법 |
| EP4420676A1 (en) | 2023-02-24 | 2024-08-28 | Medizinische Hochschule Hannover | Chimeric antigen receptor |
| WO2024175805A1 (en) | 2023-02-24 | 2024-08-29 | Medizinische Hochschule Hannover | Chimeric antigen receptor |
| WO2024194605A1 (en) | 2023-03-17 | 2024-09-26 | Quell Therapeutics Limited | Treg therapy |
| EP4434539A1 (en) | 2023-03-20 | 2024-09-25 | Medizinische Hochschule Hannover | Chimeric antigen receptor |
| WO2024194355A1 (en) | 2023-03-20 | 2024-09-26 | Medizinische Hochschule Hannover | Chimeric antigen receptor |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6235873B1 (en) * | 1999-07-31 | 2001-05-22 | The Rockefeller University | Constitutively active transcription factors and their uses for identifying modulators of activity including dysproliferative cellular changes |
| JP2010531138A (ja) * | 2007-06-13 | 2010-09-24 | ラ ホヤ インスティテュート フォア アラージー アンド イムノロジー | 制御性ｔ細胞ならびに同製造および使用方法 |
| US8658159B2 (en) * | 2008-06-30 | 2014-02-25 | Versitech Limited | Method to induce and expand therapeutic alloantigen-specific human regulatory T cells in large-scale |
| JP2017518053A (ja) * | 2014-06-06 | 2017-07-06 | メモリアル スローン−ケタリング キャンサー センター | メソセリン標的化キメラ抗原受容体およびその使用 |
| EP3158064A1 (en) * | 2014-06-17 | 2017-04-26 | Cellectis | Cd123 specific multi-chain chimeric antigen receptor |
| US11111505B2 (en) * | 2016-03-19 | 2021-09-07 | Exuma Biotech, Corp. | Methods and compositions for transducing lymphocytes and regulating the activity thereof |
-
0
- MA MA045498A patent/MA45498A/fr unknown
-
2017
- 2017-06-15 EP EP17814140.4A patent/EP3472305A4/en not_active Withdrawn
- 2017-06-15 WO PCT/US2017/037794 patent/WO2017218850A1/en not_active Ceased
- 2017-06-15 CA CA3027546A patent/CA3027546A1/en active Pending
- 2017-06-15 US US16/310,668 patent/US20190322983A1/en not_active Abandoned
- 2017-06-15 AU AU2017285319A patent/AU2017285319A1/en not_active Abandoned
- 2017-06-15 JP JP2018565336A patent/JP2019518460A/ja not_active Withdrawn
- 2017-06-15 CN CN201780037655.8A patent/CN109415698A/zh active Pending
-
2022
- 2022-02-15 JP JP2022021158A patent/JP2022058995A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019518460A5 (enExample) | ||
| Lopes et al. | The immune microenvironment in multiple myeloma: friend or foe? | |
| Lupo et al. | Natural killer cells as allogeneic effectors in adoptive cancer immunotherapy | |
| Visperas et al. | Are regulatory T cells defective in type 1 diabetes and can we fix them? | |
| Takamura et al. | Premature terminal exhaustion of Friend virus-specific effector CD8+ T cells by rapid induction of multiple inhibitory receptors | |
| Arroyo Hornero et al. | CD70 expression determines the therapeutic efficacy of expanded human regulatory T cells | |
| Trzonkowski et al. | Ex vivo expansion of CD4+ CD25+ T regulatory cells for immunosuppressive therapy | |
| Titov et al. | Knowns and unknowns about CAR-T cell dysfunction | |
| Dwyer et al. | Expression of CD39 by human peripheral blood CD4+ CD25+ T cells denotes a regulatory memory phenotype | |
| Ferreras et al. | SARS-CoV-2-specific memory T lymphocytes from COVID-19 convalescent donors: identification, biobanking, and large-scale production for adoptive cell therapy | |
| Rudak et al. | MAIT cell-mediated cytotoxicity: Roles in host defense and therapeutic potentials in infectious diseases and cancer | |
| Bahri et al. | Ectonucleotidase CD38 demarcates regulatory, memory-like CD8+ T cells with IFN-γ-mediated suppressor activities | |
| Sierra et al. | Tumor-experienced human NK cells express high levels of PD-L1 and inhibit CD8+ T cell proliferation | |
| KR20210093908A (ko) | Ny-eso-1 t 세포 수용체 및 이의 사용 방법 | |
| Koguchi et al. | Preformed CD40L is stored in Th1, Th2, Th17, and T follicular helper cells as well as CD4+ 8− thymocytes and invariant NKT cells but not in Treg cells | |
| EP2807250B1 (en) | Use of pdl1 expressing cells to convert t cells into regulatory t cells | |
| Winstead et al. | Regulatory CD4+ CD25+ Foxp3+ T cells selectively inhibit the spontaneous form of lymphopenia-induced proliferation of naive T cells | |
| Krummey et al. | Low-affinity memory CD8+ T cells mediate robust heterologous immunity | |
| Hefazi et al. | Regulatory T cell therapy of graft-versus-host disease: advances and challenges | |
| JP2018524987A5 (enExample) | ||
| CN112888481A (zh) | 包含tnfr2结构域的新型car构建体 | |
| WO2013192215A1 (en) | Compositions and methods for diminishing an immune response | |
| Fu et al. | Helper T-cell differentiation in graft-versus-host disease after allogeneic hematopoietic stem cell transplantation | |
| Bachiller et al. | Natural killer cells in immunotherapy: are we nearly there? | |
| Bourgeois et al. | CD25+ CD4+ regulatory T cells and memory T cells prevent lymphopenia-induced proliferation of naive T cells in transient states of lymphopenia |